Advertisement
Research Article

IL-2 Immunotherapy Reveals Potential for Innate Beta Cell Regeneration in the Non-Obese Diabetic Mouse Model of Autoimmune Diabetes

  • Yaiza Diaz-de-Durana equal contributor,

    equal contributor Contributed equally to this work with: Yaiza Diaz-de-Durana, Janet Lau

    Affiliation: Genetics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    X
  • Janet Lau equal contributor,

    equal contributor Contributed equally to this work with: Yaiza Diaz-de-Durana, Janet Lau

    Affiliation: Genetics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    Current address: Genentech, South San Francisco, California, United States of America

    X
  • Deborah Knee,

    Affiliation: Biotherapeutics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    X
  • Christophe Filippi,

    Affiliation: Genetics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    X
  • Marco Londei,

    Affiliation: Translational Medicine, Novartis Institutes of Biomedical Research, San Diego, California, United States of America

    Current address: Bristol-Myers Squibb, Princeton, New Jersey, United States of America

    X
  • Peter McNamara,

    Affiliation: Pharmacology Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    X
  • Marc Nasoff,

    Affiliation: Biotherapeutics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    X
  • Michael DiDonato,

    Affiliation: Structural Biology Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    X
  • Richard Glynne mail,

    rglynne@gnf.org

    Affiliation: Genetics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    X
  • Ann E. Herman

    Affiliation: Genetics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

    Current address: Genentech, South San Francisco, California, United States of America

    X
  • Published: October 24, 2013
  • DOI: 10.1371/journal.pone.0078483

About the Authors

Yaiza Diaz-de-Durana, Janet Lau, Christophe Filippi, Richard Glynne, Ann E. Herman
Genetics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America
Deborah Knee, Marc Nasoff
Biotherapeutics Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America
Marco Londei
Translational Medicine, Novartis Institutes of Biomedical Research, San Diego, California, United States of America
Peter McNamara
Pharmacology Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America
Michael DiDonato
Structural Biology Department, Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America

Corresponding Author

Email: rglynne@gnf.org

Competing Interests

The authors declare that they were all employees of the Genomics Institute of the Novartis Research Foundation or Novartis Institutes of Biomedical Research, and owned stock in Novartis (except YD and JL), at the time this work was completed. This does not alter their adherance to all PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: YD JL AEH. Performed the experiments: YD JL. Analyzed the data: YD JL AEH. Wrote the manuscript: JL AEH YD RG CF. Pharmacology support: PM. Protein sciences support: MD. Biotherapeutics support: DK MN. Translational sciences support: ML.